Investigating how immune responses during cancer treatment can lead to kidney injury
Official title: Antigen-specific T cells in immunotherapy-associated acute kidney injury
Funded at Washington University · NIH-11170211 · Data updated 2026-11-12
This study is looking at how immunotherapy, a popular cancer treatment, can sometimes harm the kidneys, and it aims to find ways to prevent this damage so that patients can continue their cancer treatment safely.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | February 1, 2024 |
| Project end | January 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $304,391 |
| NIH project number | 7R01DK137980-02 |
| Project ID | NIH-11170211 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients who are receiving immunotherapy and experiencing or at risk of acute kidney injury.
✕Less likely to help
Patients who are not undergoing immunotherapy or those without kidney issues may not benefit from this research.
What this research studies
This research focuses on understanding how immunotherapy, a common cancer treatment, can inadvertently cause kidney damage, specifically acute kidney injury. The study aims to identify the immune cells and specific kidney-related antigens involved in this adverse effect. By analyzing the mechanisms behind this kidney injury, the researchers hope to develop targeted therapies that can prevent or mitigate these harmful immune responses without compromising cancer treatment. Patients receiving immunotherapy who experience kidney issues may benefit from insights gained through this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments that protect kidney function in patients undergoing immunotherapy for cancer.
How similar studies have gone: Previous research has shown that understanding immune responses can lead to better management of treatment-related side effects, suggesting potential for success in this area.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Murakami, Naoka — Washington University
- Study coordinator: Murakami, Naoka
Related research
Other NIH-funded projects on the same topics.
-
How cancer immunotherapy can trigger T cells to damage the kidneys
This project looks for the specific immune T cells and targets that cause sudden kidney injury in people treated with cancer immunotherapy.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.